Article
Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.
Clinical colorectal cancer - 1 Mar 2023
Ten Hoorn Sanne, Mol Linda, Sommeijer Dirkje W, Nijman Lisanne, van den Bosch Tom, de Back Tim R, Ylstra Bauke, van Dijk Erik, van Noesel Carel J M, Reinten Roy J, Nagtegaal Iris D, Koopman Miriam, Punt Cornelis J A, Vermeulen Louis
Abstract excerpt
BACKGROUND: Here we present updated survival of the CAIRO2 trial and assessed whether the addition of anti-EGFR to anti-VEGF therapy could still be an effective treatment option for patients with extended RAS/BRAF wildtype and left-sided metastatic colorectal cancer (mCRC). MATERIALS AND METHODS: Retrospective updated survival and extended RAS and BRAF V600E mutational analysis were performed in the CAIRO2 trial,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.